Billion-dollar babies

Billion-dollar babies
For example, Pfizer acquired Lipitor, its blockbuster cholesterol-lowering pill, as part of its takeover of Warner-Lambert. Likewise, when Gilead bought Pharmasset, one of the assets it acquired was Sovaldi, a hepatitis-C treatment which is now one of …
Read more here.

Indiana Public Media News
The ACLU of Indiana is taking the state to court over Medicaid treatment for hepatitis C. The cure for hepatitis C can cost as much $ 100,000. Medicaid programs can get the drugs for cheaper, but they're still expensive. So, to limit the burden on the …
Read more here.

Hepatitis C cure: faster, less expensive treatment shows positive results
Just last year, the FDA has given their approval to a new drug called Harvoni for the treatment of Hepatitis C. So, this was supposed to be a good news for those who have been suffering from the infectious disease, which mostly targets a person's liver …
Read more here.

Hep C and long-term costs: Why safety is suddenly part of the value equation
When Gilead's Sovaldi (sofosbuvir) was approved in December 2013, it was viewed as the beginning of a new era in hepatitis C treatment and the end of an old paradigm. Suddenly, a disease that was difficult to treat and could rage on for years could be …
Read more here.

Hepatitis C exposure news: Nearly 5000 patients in Utah hospital possibly exposed
Nearly 5,000 patients from a hospital in Utah have been warned about being possibly exposed to Hepatitis C virus. Health officials from Utah Department of Health have sent warning letters to patients from McKay-Dee Hospital in Ogden about possibly …
Read more here.

Hep C patients to get NHS access to three new therapies
NICE is recommending Harvoni (ledipasvir-sofosbuvir) in various different scenarios for patients with hepatitis C genotypes 1 and 4. Compared with current treatment, Harvoni offers an oral, shortened, and interferon‑free therapy and represents “a major …
Read more here.

Gilead Sciences Stock Forecast For 2016
Figures released in Europe show that 80,000 Europeans have started on a Gilead hepatitis C drug, generating nearly $ 3 billion in revenue from the beginning of 2015. When including the 32,000 hepatitis C patient count of 2014, it is estimated that …
Read more here.


Leave a Reply